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The  presence  of antibodies  against  basement  membrane  antigens  of  the 
glomerulus (GBM) 1 (1) and anterior lens capsule (ALC) (2) in the sera of patients 
with Goodpasture syndrome, and of the GBM in the sera of those with poststrep- 
tococcal glomerulonephritis (PSGN)  (3)  was  recently reported.  The  first  two 
studies show that antibodies in the patients' sera react with collagenase-resistant 
sequences of basement membrane (BM) collagen (type IV) corresponding to the 
globular NC-1  domain; the third study shows that the sera from patients with 
PSGN react with heparan sulfate proteoglycan (PG) and a  galactosamine-con- 
taining PG. Anti-BM antibodies can produce a spectrum of diseases ranging from 
mild  to  severe  and  rapidly  progressive  glomerulonephritis,  with  or  without 
pulmonary hemorrhage, a condition seen in Goodpasture syndrome (4).  Unlike 
the situation with anti-BM-induced disease, where the antibody is deposited in 
a linear fashion on the GBM, in PSGN the immunoglobulin is found in granular 
deposits along the GBM (5).  Ultrastructurally, the glomerular lesions in PSGN 
are characterized by large subepithelial deposits that contain antibody, comple- 
ment, and possibly streptococcal antigens (6).  BM collagen (type IV) has been 
isolated from several tissues, including the glomerulus (7,  8),  the ALC (9-11), 
the placenta (12), and the mouse EHS tumor (13).  When obtained by nondegra- 
dative methods, it consists of two identical polypeptide chains, [o~l(IV)]2, and a 
third chain, a2(IV),  having Mr of 185,000  and  170,000  respectively (13,  14). 
These chains form a  triple helical molecule. Chains having lower Mr (125,000 
and  115,000  as  well as  95,000  and  75,000)  have been obtained after pepsin 
digestion of basement membranes (12,  15).  Rotary shadowing electron micros- 
copy has revealed molecules having a  filamentous, helical, collagenous domain 
terminating in  a  noncollagenous, globular domain at  the carboxyl end (NC-1 
domain);  at  the  amino  end,  the  molecule terminates  in  a  highly crosslinked 
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collagenous region termed 7-S domain (14,  16). Upon coilagenase digestion at 
37°C these two domains survive, one by virtue of its composition (NC-1), and 
the other by virtue of its high disulfide and lysyl-derived crosslinking (17). 
Laminin is a large (Mr 900,000) glycoprotein component of BMs composed of 
at least three highly crosslinked subunits (18).  The isolation of a large glycopro- 
tein from GBM was  first reported in  1966  (7). Immunochemical studies on a 
similar glycoprotein, isolated after collagenase digestion of GBM, were reported 
in  1972  (19).  It  is  very  likely  that  the  latter  studies  were  dealing with  the 
glycoprotein we now refer to as laminin. The proportion of laminin with respect 
to type IV collagen varies among BM but no mature BM is totally devoid of it 
(20). 
A number of studies (1-3, 21) suggest that the antibodies in the sera of patients 
with glomerulonephritis may be  directed against a  variety of glomerular and 
nonglomerular antigens.  The demonstration by Fillit et al.  (3)  that sera  from 
patients with acute  PSGN  (APSGN)  react  with heparan  sulfate PG suggested 
that  such  patients  may  have  antibodies  against  other  BM  components.  We 
therefore decided to investigate this possibility. Since there is a  high degree of 
immunologic crossreactivity among heterologous basement membranes (3,  19), 
and since sera from patients with Goodpasture syndrome react with bovine ALC 
collagen (2), we decided to test the reactivity of the latter with sera from patients 
with APSGN. Our data show that sera from patients with APSGN have antibodies 
that react not only with heparan sulfate PG but also with type IV collagen and 
[aminin. No reaction was noted with fibronectin. We also present evidence that 
the collagenase-resistant fragment of type IV collagen corresponding to the 7-S 
domain contains the epitope or epitopes against which the anti-type IV collagen 
antibodies react.  This is a  significant difference in  the reactivity of sera from 
patients with APSGN compared to those from patients with Goodpasture syn- 
drome, and may explain the reported difference in the distribution of antibody 
on the GBM between the two diseases. 
Materials and Methods 
Reagents 
Human sera  from patients  with APSGN  and  normal  controls  were  obtained  from 
Trinidad. Rabbit anti-mouse laminin (EHS tumor) was obtained from Betbesda Research 
Laboratories,  Gaithersburg,  MD (6265 SA). Normal  rabbit  serum  was obtained from 
Cappel Laboratories,  Malvern, PA (5012-1380), and rabbit anti-human fibronectin was 
purchased from Calbiochem-Behring Corp., San Diego, CA (341643). 
Rabbit Antisera Against BM Collagen (type IV) 
These sera are available at the laboratory of N. Kefalides, and were prepared against 
bovine ALC type IV collagen as described by Brinker et al. (14). 
Preparation of antigens 
BM collagen (type  IV). Native, undegraded type IV collagen was extracted from bovine 
ALC with 0.5 M acetic acid (22), and purified on a DEAE-cellulose column as described 
by Brinker  et al. (14). Rotary shadowing electron  microscopy revealed procollagen-like 
molecules having a helical domain (364 nm), a carboxyl terminal, a globular domain (11 
nm), and tetramers of such molecules overlapping at the amino terminus to form the 7-S 
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Bacterial collagenase-resistant fractions  of BM collagen.  The  insoluble  ALC  that  re- 
mained after extraction  with  0.5  M  acetic acid were subjected to bacterial  collagenase 
digestion (19).  -500 mg of lyophilized ALC was suspended in  18 ml of 0.1  M  Tris-0.4 
M  NaCI, pH 7.4 buffer containing protease inhibitors (N-ethylmaleimide, 3 raM; PMSF, 
1  mM)  and  CaC12,  6  mM.  Bacterial  collagenase  (CLSPA-Worthington  Biochemicals, 
Freehold,  N  J)  was  added  at  an  enzyme/protein  ratio  of 1:100,  and  the  digestion  was 
allowed to proceed at 37°C for 20 h. At the end of this period,  1 ml of 100 mM EDTA 
was added, and the solubilized protein was separated by centrifugation at 30,000 g for 1 
h  at 4°C. The supernatant  was dialyzed exhaustively against distilled  water at 4°C and 
lyophilized. For gel filtration, 40 mg of the lyophilized digest was dissolved overnight at 
4°C in a solution of 1 M CaCI~ containing 50 mM Tris, pH 8.5, and 20 ~g pepstatin (P- 
4265; Sigma Chemical Co., St. Louis, MO). The solution was warmed for 30 min at 45°C, 
and then centrifuged at 20,000 g for 30 rain at 22°C. The pellet was discarded and the 
supernatant was placed on a 6% agarose A-5m column (1.6 cm ×  145 cm). Proteins were 
eluted with a buffer containing 1 M CaCI2, 50 mM Tris-HCI, pH 7.5, at room temperature 
at a flow rate of 14.8 ml/h (Fig.  1) (15). The fractions were dialyzed at 4°C against water 
and lyophilized. 
Humanfibronectin.  Human fibronectin was isolated from human plasma on a gelatin- 
Sepharose column as described previously (23). 
ELISA 
Antibodies against type IV procollagen and its fractions, and against laminin in patients 
with  APSGN were detected  by using the  ELISA. The assay was performed  essentially 
according to previously described  methods  (24).  The wells of Immunolon I  microtiter 
plates (Dynatech, Inc., Alexandria, VA) were coated with the appropriate antigen. Native 
type IV procollagen was coated in Voller's buffer (0.15 M  Na2 COs, 0.35 M  NaHCOs, 
0.2% NAN3) at a concentration of 600 rig/well. The noncoUagenous NC-1 domain of type 
IV collagen (Fig.  1, peak V) as well as aggregates of NC-1, i.e., Peaks I and II of Fig.  1 
were coated  in  Voller's buffer,  0.5  M  acetic acid,  or 6  M  guanidine-HCI.  ELISA was 
performed  for  human  fibronectin  and  the  7-S  fraction  (Fig.  1,  peak  II1) of type  IV 
collagen, as described for the native type IV collagen molecule. Mouse laminin (6260LA; 
Bethesda Research Laboratories, Gaithersburg,  MD) was coated in 0.5 M acetic acid, also 
at 600 ng/well. The plates were then incubated overnight at 4°C. The wells were washed 
three times over 30 rain with  0.05%  Tween 20 in PBS (PBS-T), followed by a  90-min 
incubation at room temperature with goat anti-human polyvalent Ig-alkaline phosphatase 
conjugate (A-5034; Sigma Chemical Co.) diluted 1:300 in PBS-T. The wells were washed 
again  as  above,  the  phosphatase  substrate  (p-nitrophenyl  phosphate  disodium,  104-0; 
Sigma Chemical Co.) was allowed to incubate for 30 min, the reaction was stopped by the 
addition of 2 M NaOH (50 #l/well), and the reaction product was quantitated by measuring 
absorbance at 405 nm with a Dynatech microELISA minireader. 
Competitive ELISA 
Inhibition  experiments  with  type IV procollagen and  laminin  revealed  inhibition  of 
APSGN  serum  reactivity  to  both  type  IV  procollagen  and  laminin.  In  this  case,  a 
competitive  ELISA was  performed.  Wells  were  coated  as  above  with  either  type  IV 
procollagen or laminin at a concentration of 600 ng/well. Another plate was coated with 
1%  BSA albumin  (Calbiochem-Behring Corp.)  in Voller's buffer and  left  overnight at 
4°C. 
Various concentrations  of type  IV procollagen or  laminin  (0-100,000  ng/ml)  were 
mixed separately with a constant amount of APSGN serum or control serum diluted 1:25 
in PBS-T, were then placed in the BSA-treated wells, and were incubated overnight at 
4°C.  After the overnight incubation,  these mixtures were placed in the antigen-coated 
wells (containing either type IV procollagen or laminin) and incubated for 30 min. The 
unbound antibody was removed by washing with PBS-T three times for a total of 30 min. 
The goat anti-human  conjugate was then  added and the  assay continued as described 
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Immunoblot 
To further confirm the presence of antibodies to type IV procollagen and laminin in 
the sera of patients with  APSGN, immunoblots were performed. SDS-PAGE was per- 
formed according to Laemmli (25). 
For type IV collagen, 30 #g protein was placed on each lane of a 5% polyacrylamide 
gel. For laminin, 2.2 #g protein was placed on each lane of a 4% polyacrylamide gel. 
Following electrophoresis, the gels and nitrocellulose membrane (162-0115;  Bio-Rad 
Laboratories were soaked in transfer buffer (25 mM Tris,  192 mM glycine, pH 8.3) for 
~30 rain. The proteins were then allowed to transfer overnight using a Bio-Rad Trans- 
Blot apparatus (120 V, 170-3917; Bio-Rad Laboratories). Transfer was performed at 4 ° C, 
30 V. 
Immunodetection was performed using a protocol from Vector Laboratories (Burlin- 
game, CA).  After transfer,  the  membranes were incubated in  PBS-T for 30  min.  All 
incubations were carried out at room temperature with gentle agitation. Each membrane 
was then incubated in a solution of primary antibody in PBS-T for 60 rain. In the case of 
type IV procollagen, a membrane was incubated with each of the following: rabbit anti- 
type IV procollagen antiserum, at a dilution of 1:1,000; normal whole rabbit serum, at a 
dilution of 1:1,000; APSGN serum, at a dilution of 1:100; and control human serum, at 
a dilution  1:100. 
For laminin, a membrane was incubated with rabbit anti-mouse laminin at a dilution 
of 1 : 10. Control and patient sera were used as above. 
The  membranes were  then  washed  with  PBS-T  with  three  changes  over  30  rain, 
followed by an incubation in biotinylated secondary antibody in PBS-T (Vectastain ABC 
Kit, Rabbit IgG, PK-4001 Vector Laboratories, Burlingame, CA) for 30 min. They were 
then incubated for 30 min in the Vectastain ABC reagent. Another wash was performed 
as above, but in  PBS.  Membranes were then incubated for ~15  min in the peroxidase 
substrate solution, which consisted of 2 mi of a 3 mg/ml solution of 4-chloro-l-naphthol 
in methanol, 10 ml of PBS, and 5 #l 30% H202, followed by a wash in distilled water with 
two changes over 10 rain. 
Results 
Characterization  of Antigenic Components  of BM 
BM Collagen.  The  material solubilized  by extraction  with  0.5  M  acetic acid 
and  purified  by  DEAE-cellulose  chromatography was  subjected  to  amino acid 
and  carbohydrate  analysis.  Table  I  shows  that  the  preparation  has  a  high  4- 
hydroxyproline,  3-hydroxyproline, and hydroxylysine content,  as well as a  low 
alanine  content,  which  is consistent  with previous analyses of type  IV collagen 
(14,  16).  The  equimolar  amounts  of glucose and  galactose,  as well as  the  low 
content  of mannose and  fucose  further  confirm  the  nature  of the  material  as 
type  IV  collagen  that  still  has  its  propeptide  extensions  intact  (analogous  to 
procollagen). Rotary shadowing electron microscopy revealed typical monomers 
and  their  tetramers  overlapping  at  the  amino  terminus  (7-S  domain)  (14,  16) 
(data not shown). 
Bacterial coUagenase-resistant fractions of BM.  The  bacterial  collagenase-re- 
sistant fractions of ALC were resolved into seven fractions on an agarose A-5m 
column (Fig.  1).  Amino acid analysis of peaks I  and  II revealed the noncollage- 
nous  nature  of  the  fractions,  containing  only  traces  of  hydroxyproline  and 
hydroxylysine (data not  shown).  The analyses of peaks III and V  are shown in 
Table I. Peak V  has a  noncoilagenous amino acid composition.  Note the collag- 
enous  nature  of peak  III.  The  4-hydroxyproline,  hydroxylysine,  and  glycine 
content  is  much  higher  than  that  seen  in  the  intact  type  IV collagen,  whereas 592  ANTIBODIES TO  BASEMENT  MEMBRANE  COLLAGEN AND  LAMININ 
TABLE  I 
Amino Acid and Sugar Compositions of  ALC Acetic Acid Extract and 
Collagenase-resistant Fractions 
Amino acid* 
Acetic acid  Collagenase digest 
extract DEAE 
flow-through  Peak III*  Peak V* 
volume 
Cysteic acid 
3-Hydroxyproline  12.08  4.83  -- 
Methionine  sulfoxide  --  2.26  1.70. 
4-Hydroxyproline  82.55  96.28  Trace 
Aspartic  40.51  39.32  59.73 
Threonine  31.78  35.04  64.80 
Serine  51.85  32.50  87.30 
Glutamic  105.42  89.63  93.33 
Proline  67.34  66.96  76.45 
Glycine  263.97  316.24  100.54 
Alanine  44.38  25.76  94.57 
Cystine (reduced)  9.48  32.08  34.36 
Valine  30.72  50.04  53.25 
Methionine  13.69  5.08  15.45 
lsoleucine  28.93  27.86  45.04 
Leucine  56.15  42.66  73.20 
Tyrosine  17.30  17.35  36.63 
Phenylalanine  33.93  17.76  43.28 
Hydroxylysine  35.27  41.41  4.48 
Lysine  21.16  l 1.13  30.24 
Histidine  15.48  12.24  36.14 
Arginine  38.02  41.09  57.10 
Sugars§ 
Mannose  6.84  34.07  1.85 
Fucose  1.46  11.093  1.66 
Galactose  30.77  44.40  2.57 
Glucose  33.90  36.37  2.51 
* Residues per thousand. 
* Fractions  isolated after bacterial  collagenase digestion  of ALC and gel 
filtration. 
§ ug/mg protein. 
the  alanine  content  is  now  significantly  lower.  Note  the  high  reduced  cystine 
content,  indicative  of the  high  crosslinking  within  the  7-S domain.  The  carbo- 
hydrate content again  is characterized by the equimolar amount of glucose and 
galactose, but one now sees a significantly higher content of mannose and fucose. 
Rotary shadowing electron  microscopy revealed small globular pieces in peak 
V  and  aggregates  of these  in  peaks  1 and  lI  of Fig.  1.  Peak  III was  composed 
entirely of the 7-S domain.  (data  not shown). 
Laminin.  The  amino  acid  and  carbohydrate  analyses  of laminin  from  the 
mouse EHS tumor was similar to that published  earlier (13) (data not shown). 
Immunologic Studies of BM Components 
Type IV collagen.  The native, undegraded type IV collagen obtained after 0.5 
M  acetic acid  extraction  of ALC  was tested  by ELISA and  by immunoblotting E 
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FIGURE  1.  Gel  filtration  of bacterial  collagenase  digest  of ALC  on  a  6%  agarose  A-5m 
column.  Proteins were eluted with a  buffer containing  1  M  CaCl~ in  50  mM Tris-HCl, pH 
7.5.  Peak I is the void volume. 
using an antiserum prepared against it in rabbits,  as well as human sera from 
controls and patients with APSGN. 
Using an ELISA, type IV collagen, at a concentration of 600 ng/well, reacted 
with diluted sera from five patients with APSGN and five controls (Fig. 2).  A 
clear titration curve of reactivity was observed as the serum was diluted and the 
type IV collagen antigen concentration was held constant. Except for the serum 
from patient 4, who had a much higher titer, the remainder of the patients' sera 
had comparable titers and presented similar titration curves. The sera from the 
five control individuals showed very little reactivity with the antigen, even at the 
lowest serum dilution. This experiment suggests that the sera contained anti- 
bodies against type IV collagen and that IgG in the serum being tested accounted 
for the observed antibody binding. 
To further verify the nature of the antibody in the APSGN sera, a inhibition 
ELISA was performed using varying concentrations of ALC type IV collagen 
and a constant dilution of the patients' sera against the antiserum to ALC type 
IV collagen. In Fig. 3, sera from patients 3 and 4 were inhibited from reacting 
with type IV collagen up to an antigen concentration of 10,000 ng/ml, suggesting 
that antibodies in the patients' sera were indeed directed against determinants 
of the type IV collagen molecule. 
To determine whether antibodies in the patients' sera were directed against 
any of the well-defined domains of type IV collagen, the ELISA was used with 594  ANTIBODIES  TO  BASEMENT  MEMBRANE  COLLAGEN  AND  LAMININ 
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FIGURE  2.  An  ELISA  study  with  type  1V  collagen  isolated  from  ALC.  Antigen at  600 
ng/well. The reactivity of sera from five patients with APSGN and five controls are shown. 
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FIGURE  3.  An  ELISA  study with  type  IV  collagen  from  ALC.  Two  APSGN  sera  and  a 
control serum (1:25 dilution) were inhibited with type IV collagen at varying concentrations. 
The APSGN  sera were inhibited up to an antigen concentration of 10,000 ng/ml. The reaction 
with the control serum is unchanged throughout the range of antigen concentrations. 
material from peaks III and V  as well as peaks I and II of the collagenase digest 
(Fig.  1).  Fig.  4B  shows  that  the  7-S  domain  (peak  III)  has  a  much  stronger 
reactivity compared to the noncollagenous domain NC-1 (peak V) and its aggre- 
gates in peaks I and II. 
The reactivity of the APSGN sera with type IV collagen and its fractions was 
further confirmed by performing immunoblots. Fig. 5A clearly shows a positive 
reaction of type IV collagen with its rabbit antiserum, as well as with the serum 
from a patient with APSGN. Similarly, peak III (7-S domain) of the collagenase KEFALIDES  ET  AL.  595 
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FIGURE 4.  An ELISA study with fibronectin and collagenase-resistant fractions of type IV 
collagen.  (A)  Reaction of an  APSGN serum  wtih fibronectin  at different  concentrations. 
Patient  and control  sera show little or no reactivity with fibronectin.  (B) Reactivity of an 
APSGN serum with collagenase-resistant domains of type IV collagen. Peak V, monomer of 
NC-I domain; peaks I and II, aggregates of NC-1 domain; peak III, 7-S domain. The control 
serum was reacted with the same peak material as the APSGN serum (O---O),  and the values 
represent the average from all four peaks. 
digest  of  ALC  shows  a  clear  reaction  with  the  rabbit  antiserum  to  type  IV 
collagen, as well as with serum from a patient with APSGN (Fig.  5B). 
Laminin.  The  mouse  iaminin  isolated  from  the  EHS  tumor  was  tested  by 
ELISA  and  by  immunoblotting  using  an  antiserum  prepared  commercially 
against it, as well as with human  sera from controls and patients with APSGN. 
Fig.  6  shows the reactivity of mouse laminin at a  concentration  of 600  ng/well 
with  increasing  dilutions  of the  control  and  patients'  sera.  As  was  noted  with 
type IV collagen, a clear titration curve of reactivity was obtained with increasing 
serum dilution. 
The  presence  of antibodies  against  laminin  in  the  sera  from  patients  with 
APSGN was further confirmed by carrying out an inhibition of ELISA (Fig.  7). 
The reaction  of laminin  with  the  APSGN sera was inhibited  by the antigen  up 
to a  concentration  of 10,000  ng/ml,  suggesting that antibodies  in  the  patients' 
sera were directed against determinants of the laminin molecule. 
An  experiment  using  ELISA  with  human  laminin  isolated  from  placental 
membranes (27) showed comparable reactivity of two APSGN sera with that of 
mouse taminin (data not shown). 
Fig.  8  shows an  immunoblot of mouse  laminin  with  a  serum  from a  patient 
with APSGN. The reactivity of the serum with laminin is clearly demonstrated. 
Fibronectin.  The reactivity by ELISA of human fibronectin with an APSGN 
serum  was  weak  and  no  higher  than  that  obtained  with  a  control  serum  (Fig. 
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FIGURE 5.  Immunoblots of type IV collagen and of the 7-S domain. (A) Reaction ofreduced 
type IV collagen with (I) rabbit anti-Type IV serum, (2) APSGN  serum, (3) control serum, 
and (4) normal rabbit serum. (B) Reaction of reduced collagenase resistant material from peak 
III (7-S domain) with (1) rabbit anti-type IV, (2) ASPGN  serum, (3) control serum, and (4) 
normal rabbit serum. 
Discussion 
This study is an  extension  of the recently published  work (3) which demon- 
strated  that  sera from patients  with acute or chronic  PSGN contain  antibodies 
against  proteoglycans  derived  from  bovine  and  human  glomeruli  (3).  This 
observation suggested that,  in conditions in which tissue injury can occur, as in 
bacterial  or viral  infections,  release into the circulation  of antigenic  fragments 
from critical tissue regions can take place, leading to the development of specific 
autologous  antibodies.  It  was  further  suggested  that,  in  the  case  of  PSGN, 
autoantibodies to other antigenic components of the glomerulus, such as type IV 
collagen and laminin, can develop as well. The data obtained in the present study 
support this view. 
Purified type IV collagen has been obtained by nondegradative methods from 
bovine lens capsule, the only type of normal BM that allows the isolation of intact 
type IV collagen molecules (14, 18). This has permitted the isolation of structural 
domains  from  such  molecules and  allowed  their  ultrastructural  and  immuno- 
chemical characterization  (14, 28). The sera from patients with APSGN reacted 
with intact type IV collagen molecules as shown by ELISA (Fig. 2).  The nature 
of the antibody in  the  APSGN  sera  was verified by performing  a  competitive KEFALIDES  ET  AL,  597 
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FIGURE 6.  An EL1SA study with mouse laminin. Antigen at 600 ng/well. The reactivity of 
sera from five patients with APSGN and five controls are shown. 
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FIGURE 7.  An  ELISA study with mouse laminin. Two APSGN sera and a control  serum 
(1:25 dilution) were inhibited with laminin at varying concentrations. The APSGN sera were 
inhibited  up to an antigen  concentration  of 10,000 ng/ml.  The reaction  with the  control 
serum is unchanged throughout the range of antigen concentrations. 
ELISA. Sera from two patients were tested  (Fig.  3) and exhibited  inhibition  of 
the immunologic reactivity of type IV collagen with its antiserum. The specificity 
of the antibodies against type IV collagen was confirmed by performing immu- 
noblots (Fig.  5A). 
The collagenase-resistant domains of type IV collagen were obtained from the 
insoluble ALC BM (Fig.  1). On the basis of chemical analyses and ultrastructural 
studies,  the  NC-1  domain  is noncollagenous  (Fig.  1,  peaks I,  II, IV and  V  and 
Table I) and globular (13,  14,  16),  whereas the  7-S domain is collagenous (Fig. 
1, peak Ill and Table I) and rod-like (13,  14,  16). The NC-1 domain is stabilized 
by interchain disulfide bonds (1, 2, 26,  29),  whereas the 7-S collagenous domain 598  ANTIBODIES  TO  BASEMENT  MEMBRANE  COLLAGEN  AND  LAMININ 
FIGURE 8.  Immunoblot of mouse laminin (LN). The reduced antigen was reacted with (I) 
rabbit anti-mouse LN, (2) ASPGN serum, (3) control serum, and (4) normal rabbit serum. A, 
Bi and B~ denote position of the respective laminin subunits. 
is  stabilized  by  both  disulfide  and  lysyl-derived covalent  crosslinks  (17,  30). 
Unlike the reports (1,  26) that used sera from Goodpasture syndrome patients 
and localized the antigenic determinant in the noncollagenous, globular domain 
(NC-1) of type IV collagen, in our present study, the sera from patients  with 
APSGN react predominantly with the 7-S domain (Fig. 4).  An earlier study by 
Kefalides et  al.  (2)  indicated that  sera from three  patients  with  Goodpasture 
syndrome reacted predominantly with the 7-S domain (Fig.  1, peak III). In this 
study, compared to material in peaks I, II, and V, peak III reacted more strongly 
with the APSGN sera.  However, neither the NC-1, nor the 7-S domain of the 
type IV collagen reacted as strongly as did the intact molecule (Figs.  2 and 4A). 
This suggests that a major portion of the antibodies in the APSGN sera must be 
directed against conformational determinants. The higher reactivity of the 7-S 
domain with the APSGN sera cannot yet be explained; however, carbohydrate 
analysis (Table I, peak III) shows a significantly higher sugar content compared 
to the NC-1  domain (Table I, peak V).  It should also be noted that material in 
peak  III  contains  18  times  more  mannose  and  -7  times  more  fucose  than 
material in peak  V,  suggesting that,  in  addition to  the glucosyl-galactose unit 
linked to hydroxylysine, the 7-S domain must contain mannose-rich oligosaccha- 
ride units. The latter property may render the 7-S domain more antigenic. Little 
or no  reactivity was  noted  when pepsin-resistant  cxl(IV) and  ~2(IV)  collagen 
chains (3//,. 125,000 and 110,000, respectively) were tested against several APSGN 
sera (our unpublished observation). 
The APSGN  sera were reactive against mouse laminin both by ELISA and 
immunoblot (Figs.  6 and 8). This is not surprising, since this glycoprotein is an 
integral part of GBM and constitutes -30-40%  of its weight (20). The laminin KEFALIDES  ET  AL.  599 
molecule, which has the shape of a  cross, has several structural domains: three 
short arms with two globular domains in each, and a long arm with one globular 
domain. At present, it is not known against which of the domains the antibodies 
are directed. Unpublished studies in our laboratory (N. A. Kefalides) show that 
sera of patients  with  Goodpasture syndrome also react with mouse as well as 
human laminin. We have tested a number of sera from patients with APSGN by 
ELISA and immunoblot against a preparation of laminin from human placenta 
(27) and noted a significant degree of reactivity (our unpublished observation). 
It would appear, therefore, that autoantibodies associated with either APSGN 
or Goodpasture syndrome are directed against a variety of antigenic components 
present  in  the  GBM.  Sera  of patients  with  the above disorders may contain 
autoantibodies against other renal or extrarenal antigens. Studies by Wilson and 
Dixon (31) show that sera of patients  with Goodpasture syndrome react with 
capillaries of the choroid plexus. Clayman et al.  (32) has recently reported the 
isolation of a tubular antigen producing antitubular BM disease. As other renal 
antigens become isolated and characterized, their relationship to immunologi- 
cally-mediated renal disease could be ascertained. It has been reported (33) that 
the B-1 subunit of laminin consists of two polypeptide chains (50 nm long) having 
a coiled-coil o~-helix. A similar structure has been reported for a surface protein 
(50 nm long) isolated from group A streptococci (34). It is intriguing to speculate 
that the immunologic crossreactivity observed between GBM and the S-hemolytic 
streptococcus may be related to the structural similarity between the B-1 subunit 
of laminin and the streptococcal surface M protein. 
Cellular immune studies of glomerulonephritis by a  number of investigators 
have previously demonstrated the presence of cellular reactivity to GBM antigens 
in these patients (reviewed in 35). However, the exact biochemical nature of the 
reactive BM antigens in these cellular assays has not been defined. The demon- 
stration  in  the  present  study of antibodies  to  laminin  and  type  IV  collagen 
determinants, and in a previous report (3) to glomerular PG in poststreptococcal 
sera  lends  credence  to  the  data  derived  from  the  cellular  immune  studies 
indicating that autoimmunity to a variety of glomerular antigens may occur in 
glomerulonephritides besides  classic  anti-GBM  disease.  These  cellular studies 
have also consistently demonstrated cellular immune reactivity to streptococcal 
antigens in  patients with glomerulonephritis (35).  The possibility remains that 
streptococcal cellular reactivity in patients with glomerulonephritis is due to the 
presence  of crossreactive determinants  shared  by  the  streptococcus and  BM 
antigens (5). These crossreactive determinants may not only be protein in nature, 
but may also represent crossreactive carbohydrate epitopes (3). 
In view of the observations by Fillit et al. (3) and our current findings, it can 
be stated that autoantibodies can be produced against a range of tissue-specific 
antigens after bacterial infection. It is becoming increasingly evident that in anti- 
BM disease, the production of antibodies is not against a single antigenic com- 
ponent or a single epitope on an antigen. Rather, antibodies are produced against 
all  the  known  integral  components  of the  BM,  including  type  IV  collagen, 
laminin, PG, and possibly entactin. Our ongoing studies with sera from patients 
with  Goodpasture  syndrome also  support  this  view.  It  should  be  noted  that 
fibronectin,  which  occasionally can  be  identified  in  the  GBM  as  a  result  of 600  ANTIBODIES  TO  BASEMENT  MEMBRANE  COLLAGEN  AND  LAMIN1N 
trapping,  did  not  react  with  any  of the  APSGN  sera,  further  indicating  the 
apparent  specificity of such  autoimmune  reactivity  for  true  BM  components. 
Additional work is required to elucidate the factors that contribute to the relative 
antigenicity  of the  various domains  of type IV collagen  and  laminin,  and  the 
differences in the pathologic picture of the kidney between PSGN and Goodpas- 
ture  syndrome.  Finally,  the role of anti-BM  autoimmunity in  APSGN and the 
subsequent development of chronic PSGN requires investigation. 
Summary 
Sera from patients  with poststreptococcal glomerulonephritis  (PSGN) known 
to have antibodies to proteoglycans were studied for the presence of antibodies 
against other basement membrane (BM) components. BM collagen (type IV) was 
isolated in the native state by extracting bovine anterior lens capsule (ALC) with 
0.5 M acetic acid. The 7-S (collagenous) domain and the NC-1 (noncollagenous) 
domain of type IV collagen were obtained after bacterial collagenase digestion 
of ALC  followed by gel filtration.  Laminin  was isolated from  the mouse EHS 
tumor and fibronectin from human plasma. 
Immunologic  studies,  using an  ELISA and electroimmunoblot,  revealed the 
presence of antibodies that reacted with intact, native type IV collagen and the 
7-S collagenous domain of this  molecule.  Reaction with the NC-1  (noncollage- 
nous) domain was minimal, and not higher than that obtained with control sera. 
Laminin reaction strongly with the patients' sera, but fibronectin did not. 
Unlike  sera from  patients  with  Goodpasture  syndrome,  which  contain  anti- 
bodies primarily against the NC-1 (noncollagenous) domain of type IV collagen, 
sera  from  patients  with  acute  PSGN  contain  antibodies  against  all  the  major 
macromolecular components of BM. This difference in immunologic reactivity 
may  account  for  the  observed  differences  in  the  pathologic  picture  at  the 
glomerular level. 
Received for publication  18 November 1985. 
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